Perjeta 420 mg (Pertuzumab 420 mg / 14 ml) by Roche.
Indications: HER2-positive early and metastatic breast cancer in combination with trastuzumab and chemotherapy.
Administration: Intravenous infusion: 840 mg loading dose, then 420 mg every 3 weeks.
Storage: Store in a refrigerator at 2–8 °C. Do not freeze. Keep in the outer carton to protect from light.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Roche |
| Active ingredient | Pertuzumab 420 mg / 14 ml — HER2 dimerisation inhibitor monoclonal antibody. |
| Strength & pack | 1 vial of 14 ml. |
| Form | Concentrate for solution for infusion |
| Storage | Store in a refrigerator at 2–8 °C. Do not freeze. Keep in the outer carton to protect from light. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |